Last week the House of Representatives unanimously passed the Mikaela Naylon Give Kids a Chance Act. This legislation will give the FDA authority to direct pediatric cancer trials for combination drugs, reauthorize the Rare Pediatric Priority Review Voucher, and provide more funds for NIH pediatric drug studies. This legislation is an important step forward in the fight to close gaps in pediatric cancer research and develop more effective, less toxic medicine. We applaud the bill’s sponsors...